HK1066484A1 - Lyophilized formulation comprising olanzapine - Google Patents

Lyophilized formulation comprising olanzapine

Info

Publication number
HK1066484A1
HK1066484A1 HK04109512A HK04109512A HK1066484A1 HK 1066484 A1 HK1066484 A1 HK 1066484A1 HK 04109512 A HK04109512 A HK 04109512A HK 04109512 A HK04109512 A HK 04109512A HK 1066484 A1 HK1066484 A1 HK 1066484A1
Authority
HK
Hong Kong
Prior art keywords
olanzapine
lyophilized formulation
lyophilized
formulation
Prior art date
Application number
HK04109512A
Other languages
English (en)
Inventor
Kurt Douglas Dekemper
Alan Lee Fites
Steven L Nail
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1066484A1 publication Critical patent/HK1066484A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HK04109512A 2001-07-20 2004-12-01 Lyophilized formulation comprising olanzapine HK1066484A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30682901P 2001-07-20 2001-07-20
US38647402P 2002-06-07 2002-06-07
PCT/US2002/019799 WO2003007912A2 (en) 2001-07-20 2002-07-05 Lyophilized formulation comprising olanzapine

Publications (1)

Publication Number Publication Date
HK1066484A1 true HK1066484A1 (en) 2005-03-24

Family

ID=26975390

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04109512A HK1066484A1 (en) 2001-07-20 2004-12-01 Lyophilized formulation comprising olanzapine

Country Status (33)

Country Link
US (1) US20040176357A1 (de)
EP (1) EP1423124B1 (de)
JP (1) JP2004537546A (de)
KR (1) KR20040017330A (de)
CN (1) CN1537007A (de)
AR (1) AR036180A1 (de)
AT (1) ATE369137T1 (de)
AU (1) AU2002320134B2 (de)
BR (1) BR0211250A (de)
CA (1) CA2448724A1 (de)
CO (1) CO5540279A2 (de)
CY (1) CY1107759T1 (de)
CZ (1) CZ200484A3 (de)
DE (1) DE60221674T2 (de)
DK (1) DK1423124T3 (de)
EA (1) EA006506B1 (de)
ES (1) ES2289126T3 (de)
HK (1) HK1066484A1 (de)
HR (1) HRP20040037A2 (de)
HU (1) HUP0401157A3 (de)
IL (1) IL159098A0 (de)
MX (1) MXPA04000541A (de)
MY (1) MY135452A (de)
NZ (1) NZ529667A (de)
PE (1) PE20030281A1 (de)
PL (1) PL366614A1 (de)
PT (1) PT1423124E (de)
SI (1) SI1423124T1 (de)
SK (1) SK182004A3 (de)
SV (1) SV2003001179A (de)
UA (1) UA80095C2 (de)
WO (1) WO2003007912A2 (de)
ZA (1) ZA200400798B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058773A1 (en) * 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
WO2005070938A1 (en) 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
WO2006076124A2 (en) * 2004-12-16 2006-07-20 Nektar Therapeutics Stable, non-crystalline formulation comprising olanzapine
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
CA3087698A1 (en) * 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CN115006406A (zh) * 2021-12-28 2022-09-06 南京清普生物科技有限公司 一种稳定的奥氮平制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059947T3 (es) * 1989-09-30 1994-11-16 Eisai Co Ltd Preparados inyectables que contienen cefalosporina y utilizacion de los mismos.
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
EP1423124B1 (de) 2007-08-08
IL159098A0 (en) 2004-05-12
SI1423124T1 (sl) 2008-02-29
PL366614A1 (en) 2005-02-07
AU2002320134B2 (en) 2007-04-05
EP1423124A2 (de) 2004-06-02
ATE369137T1 (de) 2007-08-15
EA200400211A1 (ru) 2004-06-24
US20040176357A1 (en) 2004-09-09
DE60221674D1 (de) 2007-09-20
WO2003007912A2 (en) 2003-01-30
ZA200400798B (en) 2005-07-27
KR20040017330A (ko) 2004-02-26
MY135452A (en) 2008-04-30
SV2003001179A (es) 2003-07-29
CZ200484A3 (cs) 2005-01-12
CY1107759T1 (el) 2013-06-19
MXPA04000541A (es) 2004-05-04
CA2448724A1 (en) 2003-01-30
EA006506B1 (ru) 2005-12-29
SK182004A3 (en) 2004-09-08
UA80095C2 (en) 2007-08-27
HUP0401157A2 (hu) 2004-10-28
HRP20040037A2 (en) 2004-06-30
NZ529667A (en) 2006-02-24
AR036180A1 (es) 2004-08-18
WO2003007912A3 (en) 2003-05-01
PE20030281A1 (es) 2003-03-27
CN1537007A (zh) 2004-10-13
PT1423124E (pt) 2007-10-29
ES2289126T3 (es) 2008-02-01
DE60221674T2 (de) 2008-04-30
HUP0401157A3 (en) 2008-01-28
CO5540279A2 (es) 2005-07-29
JP2004537546A (ja) 2004-12-16
BR0211250A (pt) 2004-07-27
DK1423124T3 (da) 2007-12-03

Similar Documents

Publication Publication Date Title
GB2359254B (en) Formulation
HUP0302857A3 (en) Pharmaceutical formulation
GB0118689D0 (en) Pharmaceutical formulation
GB0000891D0 (en) Formulation
PL366432A1 (en) Pharmaceutical formulation
GB2380672B (en) Herbal formulation
IL159098A0 (en) Lyophilized formulation comprising olanzapine
GB2378384B (en) Herbal formulation
GB2378385B (en) Herbal formulation
GB0125492D0 (en) Formulation
GB2375048B (en) Formulation
GB2396812B (en) Formulation
HK1054508A1 (zh) 新型製劑
GB0112497D0 (en) Formulation
GB0104749D0 (en) Pharmaceutical formulation
GB0004124D0 (en) Formulation
GB0001144D0 (en) Glysophosate formulation
GB0007112D0 (en) Formulation
GB0010846D0 (en) Formulation
GB0023069D0 (en) Formulation
CA93386S (en) Ball
SI1368006T1 (sl) Nova formulacija z modificiranim sproscanjem
GB0103315D0 (en) Antibiotics
GB0124712D0 (en) Pharmaceutical formulation
GB0126734D0 (en) 152- Elevating sphere

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210705